Swift Biosciences Launches Accel-NGS 2S DNA Library Kit – Dramatically Reduces Sample Requirements For NGS Sample Prep
3/3/2014 9:02:16 AM
Ann Arbor, MI – February 28, 2014 Swift Biosciences, Inc. today announced the launch of the Accel-NGS™ 2S DNA Library Kit for Illumina Next Generation Sequencing (NGS) systems.
Incorporating patent-pending technology, the Swift “2S” kit provides linear yields from inputs ranging from 10 pg to 1 µg. PCR-free libraries can be produced from as little as 100 ng. Unlike other commercially available kits, exceptional quality and evenness of coverage are obtained even at very low levels of DNA input. The product is also is ideally suited for clinical samples such as FFPE tissues and plasma.
Accel-NGS 2S enables NGS laboratories to stock and use a single kit for their varied DNA library needs, ranging from high molecular weight DNA to limited quantity, damaged FFPE samples. In addition to whole genome sequencing, Accel-NGS 2S is also compatible with the leading hybridization capture products and is suitable for ChIP-Seq.
Built with usability in mind, the 2S protocol is readily automatable for those with high throughput applications. The wide dynamic range of input makes pre-library quantification optional, further streamlining workflow.
To learn more about how the Accel-NGS 2S DNA Library Kit accelerates NGS library preparation, please visit www.swiftbiosci.com.
About Swift Biosciences
Swift Biosciences is a small, fast-moving company focused on developing innovative enabling technologies for genomics and personalized medicine. With the launch of its line of Accel-NGS products, Swift is now applying its unique technologies to the Next Generation Sequencing market. Swift is working diligently to improve NGS sample preparation, an area that has not kept pace with the significant improvements made recently in NGS instrumentation and bioinformatics.
The company also has products for qPCR detection of mutations. Swift’s first products, launched in 2012, are based on myT® Primer technology which provides both high sensitivity and specificity in somatic mutation detection, making it ideal for cancer research and diagnostic applications. To date, Swift has developed myT Primers for common mutations in the BRAF and KRAS genes, which demonstrate the superior performance capabilities of the technology. Additional myT Primer reagents will be launched in the near future.
In December of 2012, Swift granted a non-exclusive license for myT Primers to an international diagnostics company. Swift will continue to develop myT Primers for RUO applications as well as license to other partners. To facilitate licensing by additional partners, Swift recently introduced a Technology Access Program for myT Primers.
Chief Commercial Officer
Swift Biosciences, Inc.
58 Parkland Plaza
Ann Arbor, MI 48103
Help employers find you! Check out all the jobs and post your resume.
comments powered by